A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

Inclusion criteria

• ✓. Age ≥ 18 years at the time of informed consent form (ICF) signed.
• ✓. Patients diagnosed with DPNP (defined as patients diagnosed with type 1 or type 2 diabetes and painful distal symmetric polyneuropathy).
• ✓. Patients with a pain scale of visual analog scale (VAS( ≥ 40 mm on the day of ICF signed.
• ✓. Patients who are mirogabalin naïve prior to ICF signed and planned to initiate mirogabalin treatment.
• ✓. Patients who are able to give signed ICF for study participation and willing to provide access to previous and future medical information.
• ✓. Patients who have other severe pain unrelated to DPN at baseline, which may confound the assessment of DPNP.
• ✓. Patients who previously received pregabalin ≥ 300 mg/day or gabapentin ≥ 1200 mg/day to treat DPNP and declared lack of effectiveness.
• ✓. Patients who received pregabalin, gabapentin, crisugabalin, or any other DPNP analgesic medications\* within 7 days prior to ICF signed.